EA200700402A1 - Rage-слитые белки и способы их применения - Google Patents
Rage-слитые белки и способы их примененияInfo
- Publication number
- EA200700402A1 EA200700402A1 EA200700402A EA200700402A EA200700402A1 EA 200700402 A1 EA200700402 A1 EA 200700402A1 EA 200700402 A EA200700402 A EA 200700402A EA 200700402 A EA200700402 A EA 200700402A EA 200700402 A1 EA200700402 A1 EA 200700402A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- rage
- proteins
- fusion proteins
- slip
- methods
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 abstract 4
- 108020001507 fusion proteins Proteins 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 239000003446 ligand Substances 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
Abstract
Описаны RAGE-слитые белки, содержащие последовательности полипептида RAGE, связанные со вторым, не-RAGE-полипептидом. RAGE-слитый белок может использовать домен полипептида RAGE, содержащий лигандсвязывающий сайт RAGE, и междоменный линкер, непосредственно связанный с СН-доменом иммуноглобулина. Такие слитые белки могут обеспечивать специфическое высокоаффинное связывание с лигандами RAGE. Описано также применение RAGE-слитых белков в качестве терапевтических средств для опосредуемых RAGE патологий.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59836204P | 2004-08-03 | 2004-08-03 | |
PCT/US2005/027694 WO2006017643A1 (en) | 2004-08-03 | 2005-08-03 | Rage fusion proteins and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200700402A1 true EA200700402A1 (ru) | 2007-08-31 |
EA012586B1 EA012586B1 (ru) | 2009-10-30 |
Family
ID=35427536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200700402A EA012586B1 (ru) | 2004-08-03 | 2005-08-03 | Rage-слитые белки и способы их применения |
Country Status (23)
Country | Link |
---|---|
US (2) | US20090060925A1 (ru) |
EP (1) | EP1776459A1 (ru) |
JP (1) | JP2008508882A (ru) |
KR (1) | KR20070057818A (ru) |
CN (1) | CN101010430A (ru) |
AP (1) | AP2007003893A0 (ru) |
AU (2) | AU2005271449A1 (ru) |
BR (1) | BRPI0514013A (ru) |
CA (1) | CA2575830A1 (ru) |
CR (2) | CR8897A (ru) |
EA (1) | EA012586B1 (ru) |
EC (1) | ECSP077297A (ru) |
GE (1) | GEP20105111B (ru) |
IL (1) | IL180555A0 (ru) |
MA (1) | MA28781B1 (ru) |
MX (1) | MX2007001556A (ru) |
NO (1) | NO20070062L (ru) |
NZ (1) | NZ552842A (ru) |
SG (1) | SG161242A1 (ru) |
TN (1) | TNSN07040A1 (ru) |
UA (1) | UA92154C2 (ru) |
WO (1) | WO2006017643A1 (ru) |
ZA (1) | ZA200700641B (ru) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6790443B2 (en) * | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
US7258857B2 (en) * | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
US6465422B1 (en) * | 1998-04-17 | 2002-10-15 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
JP2002526117A (ja) * | 1998-10-06 | 2002-08-20 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 細胞外新規rage結合タンパク質(en−rage)及びその使用 |
AU2002213192A1 (en) * | 2000-10-13 | 2002-04-22 | The Trustees Of Columbia University In The City Of New York | A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury |
JP2006512900A (ja) * | 2002-08-16 | 2006-04-20 | ワイス | Rage関連疾患の治療用組成物及び方法 |
WO2004100890A2 (en) | 2003-05-09 | 2004-11-25 | The Trustees Of Columbia University In The City Of New York | Rage g82s-related methods and compositions for treating inflammatory disorders |
US7470521B2 (en) * | 2004-07-20 | 2008-12-30 | Critical Therapeutics, Inc. | RAGE protein derivatives |
UA92154C2 (ru) * | 2004-08-03 | 2010-10-11 | Транстек Фарма, Инк. | Rage-слитые белки и способы их применения |
JP5188804B2 (ja) | 2004-08-03 | 2013-04-24 | トランステック ファーマ,インコーポレイティド | Rage融合タンパク質及びその使用方法 |
JP2008537874A (ja) * | 2004-09-27 | 2008-10-02 | セントカー・インコーポレーテツド | sRAGEミメティボディ、組成物、方法および使用 |
CA2601630A1 (en) * | 2005-03-17 | 2006-09-21 | The Trustees Of Columbia University In The City Of New York | Rage/diaphanous interaction and related compositions and methods |
WO2006119510A2 (en) * | 2005-05-04 | 2006-11-09 | Receptor Biologix, Inc. | Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same |
US20080207499A1 (en) * | 2005-06-29 | 2008-08-28 | Gaetano Barile | Rage-related methods for treating and preventing diabetic retinopathy |
AU2006327353B2 (en) * | 2005-12-23 | 2011-11-24 | Gcoder Systems Ab | Positioning pattern |
NZ569545A (en) * | 2006-02-09 | 2011-11-25 | Transtech Pharma Inc | Rage fusion proteins and methods of use for treating inflammation |
BRPI0711193A2 (pt) * | 2006-05-05 | 2013-06-18 | Transtech Pharma Inc | proteÍnas de fusço rage, formulaÇÕes e mÉtodos de uso dos mesmos |
EP2423221B1 (en) | 2007-01-30 | 2015-04-29 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
WO2008100470A2 (en) * | 2007-02-15 | 2008-08-21 | Transtech Pharma, Inc. | Rage - immunoglobulin fusion proteins |
US20100254983A1 (en) * | 2007-06-07 | 2010-10-07 | Ann Marie Schmidt | Uses of rage antagonists for treating obesity and related diseases |
MX2009013194A (es) | 2007-06-14 | 2010-03-30 | Galactica Pharmaceuticals Inc | Proteinas de fusion del receptor para productos finales de glicacion avanzada. |
NL2001557C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001555C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001551C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001558C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001556C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001553C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001554C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
NL2001552C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
KR20110139292A (ko) | 2009-04-20 | 2011-12-28 | 화이자 인코포레이티드 | 단백질 글리코실화의 제어 및 그와 관련된 조성물 및 방법 |
WO2013103688A1 (en) * | 2012-01-03 | 2013-07-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human soluble receptors for advanced glycation end products (srage), methods of preparing human srage, and treatment methods using srage |
CN103376328A (zh) * | 2013-07-18 | 2013-10-30 | 上海交通大学医学院附属瑞金医院 | 血清sRAGE水平的检测试剂在筛选改善胰岛素β细胞功能的糖尿病治疗药物中的应用 |
KR101645654B1 (ko) * | 2014-05-02 | 2016-08-05 | 서울대학교산학협력단 | Rage로부터 유래된 폴리펩티드 및 이를 유효성분으로 포함하는 뇌혈관질환의 예방 또는 치료용 약학적 조성물 |
WO2020056379A1 (en) | 2018-09-14 | 2020-03-19 | BioAge Labs, Inc. | Rage fusion proteins with improved stability and ligand binding affinity and uses thereof |
JP7477141B2 (ja) | 2019-02-21 | 2024-05-01 | 国立研究開発法人農業・食品産業技術総合研究機構 | 肝疾患診断技術 |
JP7479039B2 (ja) | 2019-02-21 | 2024-05-08 | 国立研究開発法人農業・食品産業技術総合研究機構 | 糖尿病診断技術 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) * | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4356108A (en) * | 1979-12-20 | 1982-10-26 | The Mead Corporation | Encapsulation process |
US4265874A (en) * | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US4867973A (en) * | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
US5567584A (en) * | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
US6018026A (en) * | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
NZ235148A (en) * | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
SE9201073D0 (sv) * | 1992-04-03 | 1992-04-03 | Kabi Pharmacia Ab | Protein formulation |
US5891341A (en) * | 1995-04-05 | 1999-04-06 | The Picower Institute For Medical Research | Compositions and devices for partitioning advanced glycosylation endproducts, and methods of their use |
CA2210684C (en) * | 1995-01-18 | 2008-01-15 | Alteon Inc. | Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts |
NO315930B1 (no) * | 1995-01-18 | 2003-11-17 | Picower Inst For Medical Res T | Anvendelse av tiazoliumforbindelser ved fremstilling av farmasöytiske preparater, preparater som inneholder forbindelsene, samt nyetiazoliumforbindelser |
US5656261A (en) * | 1995-01-18 | 1997-08-12 | The Picower Institute For Medical Research | Preventing and reversing advanced glycosylation endproducts |
US5747035A (en) * | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5864018A (en) * | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
US6555651B2 (en) * | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
US7081241B1 (en) * | 1998-10-06 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Extracellular rage binding protein (EN-RAGE) and uses thereof |
US6790443B2 (en) * | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
US7258857B2 (en) * | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
US7101838B2 (en) * | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
ZA988461B (en) * | 1997-09-18 | 1999-03-30 | Idec Pharma Corp | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
US6380165B1 (en) * | 1997-09-19 | 2002-04-30 | The Picower Institute For Medical Research | Immunological advanced glycation endproduct crosslink |
US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US6323218B1 (en) * | 1998-03-11 | 2001-11-27 | The General Hospital Corporation | Agents for use in the treatment of Alzheimer's disease |
US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
US6465422B1 (en) * | 1998-04-17 | 2002-10-15 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
US6753150B2 (en) * | 1998-10-05 | 2004-06-22 | The Trustees Of Columbia University In The City Of New York | Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
JP2002526117A (ja) * | 1998-10-06 | 2002-08-20 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 細胞外新規rage結合タンパク質(en−rage)及びその使用 |
US6605642B2 (en) * | 1999-04-05 | 2003-08-12 | City Of Hope | Inhibitors of formation of advanced glycation endproducts (AGES) |
US6787566B2 (en) * | 1999-04-05 | 2004-09-07 | City Of Hope | Breakers of advanced glycation endproducts |
US6939545B2 (en) * | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
WO2001012598A2 (en) * | 1999-08-13 | 2001-02-22 | The Trustees Of Columbia University In The City Of New York | METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
US20050170382A1 (en) * | 1999-10-06 | 2005-08-04 | The Trustees Of Columbia University In The City Of New York. | RAGE-related compositions |
JP2003516150A (ja) * | 1999-12-08 | 2003-05-13 | ジェンセット | 潜在性分泌タンパク質をコードする全長ヒトcDNA |
PT1272843E (pt) * | 2000-04-14 | 2007-10-01 | Niadyne Corp | Método para identificação de reguladores da formação de age de proteínas |
US6613801B2 (en) * | 2000-05-30 | 2003-09-02 | Transtech Pharma, Inc. | Method for the synthesis of compounds of formula I and their uses thereof |
US6825164B1 (en) * | 2000-08-14 | 2004-11-30 | The Trustees Of Columbia University In The City Of New York | Method to increase cerebral blood flow in amyloid angiopathy |
US6563015B1 (en) * | 2000-08-14 | 2003-05-13 | The Trustees Of Columbia University In The City Of New York | Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof |
AU2001296959A1 (en) * | 2000-10-02 | 2002-04-15 | Reddy Us Therapeutics, Inc | Methods and compositions for the treatment of inflammatory diseases |
AU2002213192A1 (en) * | 2000-10-13 | 2002-04-22 | The Trustees Of Columbia University In The City Of New York | A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury |
US20050244849A1 (en) * | 2000-12-15 | 2005-11-03 | Genetics Institute, Llc | Screening assays for rheumatoid arthritis |
IL156651A0 (en) * | 2000-12-29 | 2004-01-04 | Reddy Us Therapeutics Inc | Detection of compounds that modulate inflammatory responses |
RU2363707C2 (ru) * | 2001-02-19 | 2009-08-10 | Мерк Патент Гмбх | Искусственные белки с пониженной иммуногенностью |
WO2002070473A2 (en) * | 2001-03-05 | 2002-09-12 | Transtech Pharma, Inc. | Carboxamide derivatives as therapeutic agents |
AU2002245590B2 (en) * | 2001-03-05 | 2006-06-29 | Transtech Pharma, Inc. | Benzimidazole derivatives as therapeutic agents |
JP3837494B2 (ja) * | 2001-03-19 | 2006-10-25 | 国立大学法人金沢大学 | 可溶型rageタンパク質 |
US6861888B2 (en) * | 2002-01-16 | 2005-03-01 | Agilent Technologies, Inc. | High-sensitivity differential data latch system |
DK1482931T3 (da) * | 2002-03-05 | 2011-12-19 | Transtech Pharma Inc | Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE |
JP2006512900A (ja) * | 2002-08-16 | 2006-04-20 | ワイス | Rage関連疾患の治療用組成物及び方法 |
WO2004100890A2 (en) * | 2003-05-09 | 2004-11-25 | The Trustees Of Columbia University In The City Of New York | Rage g82s-related methods and compositions for treating inflammatory disorders |
US20050008649A1 (en) * | 2003-06-02 | 2005-01-13 | University Of Miami | Chimeric molecules and methods of use |
US6969545B2 (en) * | 2003-07-28 | 2005-11-29 | Deere & Company | Hydrogen storage container |
AU2004270207A1 (en) * | 2003-09-05 | 2005-03-17 | The Trustees Of Columbia University In The City Of New York | RAGE-related methods and compositions for treating glomerular injury |
US20070167360A1 (en) * | 2003-10-31 | 2007-07-19 | Yan Shi D | Methods for treating multiple sclerosis |
US20080260717A1 (en) * | 2003-10-31 | 2008-10-23 | Trustees Of Columbia University In The City Of New York | Methods for Reducing Seizure-Induced Neuronal Damage |
US7470521B2 (en) * | 2004-07-20 | 2008-12-30 | Critical Therapeutics, Inc. | RAGE protein derivatives |
JP5188804B2 (ja) * | 2004-08-03 | 2013-04-24 | トランステック ファーマ,インコーポレイティド | Rage融合タンパク質及びその使用方法 |
UA92154C2 (ru) * | 2004-08-03 | 2010-10-11 | Транстек Фарма, Инк. | Rage-слитые белки и способы их применения |
JP2008537874A (ja) * | 2004-09-27 | 2008-10-02 | セントカー・インコーポレーテツド | sRAGEミメティボディ、組成物、方法および使用 |
CA2601630A1 (en) * | 2005-03-17 | 2006-09-21 | The Trustees Of Columbia University In The City Of New York | Rage/diaphanous interaction and related compositions and methods |
US20080207499A1 (en) * | 2005-06-29 | 2008-08-28 | Gaetano Barile | Rage-related methods for treating and preventing diabetic retinopathy |
NZ569545A (en) * | 2006-02-09 | 2011-11-25 | Transtech Pharma Inc | Rage fusion proteins and methods of use for treating inflammation |
BRPI0711193A2 (pt) * | 2006-05-05 | 2013-06-18 | Transtech Pharma Inc | proteÍnas de fusço rage, formulaÇÕes e mÉtodos de uso dos mesmos |
WO2008100470A2 (en) * | 2007-02-15 | 2008-08-21 | Transtech Pharma, Inc. | Rage - immunoglobulin fusion proteins |
US20100254983A1 (en) * | 2007-06-07 | 2010-10-07 | Ann Marie Schmidt | Uses of rage antagonists for treating obesity and related diseases |
US9491184B2 (en) * | 2008-04-04 | 2016-11-08 | Samsung Electronics Co., Ltd. | Method and apparatus for managing tokens for digital rights management |
-
2005
- 2005-08-03 UA UAA200702216A patent/UA92154C2/ru unknown
- 2005-08-03 GE GEAP20059905A patent/GEP20105111B/en unknown
- 2005-08-03 CA CA002575830A patent/CA2575830A1/en not_active Abandoned
- 2005-08-03 CN CNA2005800261068A patent/CN101010430A/zh active Pending
- 2005-08-03 JP JP2007524977A patent/JP2008508882A/ja not_active Withdrawn
- 2005-08-03 EA EA200700402A patent/EA012586B1/ru not_active IP Right Cessation
- 2005-08-03 US US11/630,916 patent/US20090060925A1/en not_active Abandoned
- 2005-08-03 BR BRPI0514013-7A patent/BRPI0514013A/pt not_active IP Right Cessation
- 2005-08-03 NZ NZ552842A patent/NZ552842A/en not_active IP Right Cessation
- 2005-08-03 KR KR1020077005162A patent/KR20070057818A/ko not_active Application Discontinuation
- 2005-08-03 EP EP05779648A patent/EP1776459A1/en not_active Withdrawn
- 2005-08-03 AU AU2005271449A patent/AU2005271449A1/en not_active Abandoned
- 2005-08-03 MX MX2007001556A patent/MX2007001556A/es active IP Right Grant
- 2005-08-03 US US11/197,644 patent/US20060078562A1/en not_active Abandoned
- 2005-08-03 AP AP2007003893A patent/AP2007003893A0/xx unknown
- 2005-08-03 WO PCT/US2005/027694 patent/WO2006017643A1/en active Application Filing
- 2005-08-03 SG SG201002393-5A patent/SG161242A1/en unknown
-
2007
- 2007-01-04 IL IL180555A patent/IL180555A0/en unknown
- 2007-01-04 NO NO20070062A patent/NO20070062L/no not_active Application Discontinuation
- 2007-01-23 ZA ZA200700641A patent/ZA200700641B/xx unknown
- 2007-02-02 TN TNP2007000040A patent/TNSN07040A1/fr unknown
- 2007-02-02 MA MA29649A patent/MA28781B1/fr unknown
- 2007-02-02 CR CR8897A patent/CR8897A/es unknown
- 2007-03-02 EC EC2007007297A patent/ECSP077297A/es unknown
-
2010
- 2010-04-16 AU AU2010201531A patent/AU2010201531A1/en not_active Abandoned
-
2011
- 2011-10-20 CR CR20110557A patent/CR20110557A/es unknown
Also Published As
Publication number | Publication date |
---|---|
SG161242A1 (en) | 2010-05-27 |
AU2010201531A1 (en) | 2010-05-06 |
IL180555A0 (en) | 2007-06-03 |
US20090060925A1 (en) | 2009-03-05 |
CR8897A (es) | 2007-06-29 |
GEP20105111B (en) | 2010-11-10 |
JP2008508882A (ja) | 2008-03-27 |
EP1776459A1 (en) | 2007-04-25 |
WO2006017643A1 (en) | 2006-02-16 |
MA28781B1 (fr) | 2007-08-01 |
CR20110557A (es) | 2011-12-05 |
ZA200700641B (en) | 2008-10-29 |
BRPI0514013A (pt) | 2008-05-27 |
CA2575830A1 (en) | 2006-02-16 |
TNSN07040A1 (fr) | 2008-06-02 |
KR20070057818A (ko) | 2007-06-07 |
UA92154C2 (ru) | 2010-10-11 |
MX2007001556A (es) | 2008-03-05 |
CN101010430A (zh) | 2007-08-01 |
AP2007003893A0 (en) | 2007-02-28 |
ECSP077297A (es) | 2007-05-30 |
NZ552842A (en) | 2010-05-28 |
US20060078562A1 (en) | 2006-04-13 |
NO20070062L (no) | 2007-01-31 |
AU2005271449A1 (en) | 2006-02-16 |
EA012586B1 (ru) | 2009-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200700402A1 (ru) | Rage-слитые белки и способы их применения | |
NO20065949L (no) | RAGE-fusjonsproteiner og fremgangsmater for anvendelse av samme | |
EA200870244A1 (ru) | Слитые белки rage и способы применения | |
EA200870502A1 (ru) | Белки слияния на основе rage, их композиции и способы их применения | |
ATE455127T1 (de) | Humane anti-humane cd3-bindungsmoleküle | |
EA201691176A1 (ru) | АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ ЧЕЛОВЕКА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С β-КЛОТО, РЕЦЕПТОРАМИ FGF И ИХ КОМПЛЕКСАМИ | |
EA200801621A1 (ru) | Антитела, направленные на her-3, и их применение | |
EA200000331A1 (ru) | Фармацевтические композиции, содержащие белок плазмы | |
EA200700391A1 (ru) | Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1 | |
EA201100694A1 (ru) | Антитело к cd38 человека и его применение | |
EA200700917A1 (ru) | Способ рефолдинга рекомбинантных антител | |
MX2007008017A (es) | Polipeptidos que se ligan a br3 y usos de los mismos. | |
ATE517638T1 (de) | Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln | |
EA200601972A1 (ru) | Антитела к ингибирующим ангиогенез доменам cd148 | |
AR054165A1 (es) | Proteinas de union a il-6 | |
EA200700951A1 (ru) | БЕЛКИ, СОДЕРЖАЩИЕ ДОМЕНЫ vWFA И/ИЛИ ANT_IG | |
CU23703A3 (es) | Proteínas de fusión rage y métodos de uso | |
CU23731A3 (es) | Proteínas de fusión rage y métodos de uso | |
TW200718711A (en) | Polypeptides that bind BR3 and uses thereof | |
DE602004006566D1 (de) | Verfahren zur Diagnose und Behandlung von Metastasen und dafür nützliche Zusammensetzung | |
DK1461360T3 (da) | Konjugater omfattende et antistofspecifik for ED-8-domæner af fibronectin og deres anvendelse til påvisning og behandling af tumorer | |
EA201991493A2 (ru) | Антиген-связывающие белки человека, которые связываются с -клото, рецепторами fgf и их комплексами | |
EA202190387A1 (ru) | Антитело к cd38 человека и его применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |